Regulus Therapeutics reported $6.57M in Operating Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Alnylam Pharmaceuticals ALNY:US $ 359.99M 93.1M
Astrazeneca AZN:US 10.51B 1.79B
AstraZeneca AZN:LN 10.51B 1.79B
Biogen BIIB:US $ 1921.1M 225.6M
Celldex Therapeutics CLDX:US $ 23.43M 2.76M
Gilead Sciences GILD:US $ 6393M 89M
GlaxoSmithKline GSK:LN 6.98B 1.65B
Intercept Pharmaceuticals ICPT:US $ 98.85M 14.42M
Intrexon XON:US $ 49.92M 5.21M
Lexicon Pharmaceuticals LXRX:US 23.42M 1.93M
Ligand Pharmaceuticals LGND:US $ 53.5M 6.24M
Merk MRK:US $ 10332M 386M
Regulus Therapeutics RGLS:US $ 6.57M 391K
Sangamo Biosciences SGMO:US $ 73.49M 5.61M
Spectrum Pharmaceuticals SPPI:US $ 14.06M 22.79M
Takeda 4502:JP 874.91B 90.1B
Vital Therapies VTL:US $ 21.44M 286K
YTE INCY:US $ 616.69M 135.42M